PMID- 36737821
OWN - NLM
STAT- MEDLINE
DCOM- 20230209
LR  - 20230209
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 18
IP  - 1
DP  - 2023 Feb 4
TI  - Deciphering the protective effect of Buzhong Yiqi Decoction on osteoporotic 
      fracture through network pharmacology and experimental validation.
PG  - 86
LID - 10.1186/s13018-023-03545-7 [doi]
LID - 86
AB  - BACKGROUND: Osteoporotic fracture (OPF) is one of the most common skeletal 
      diseases in an aging society. The Chinese medicine formula Buzhong Yiqi Decoction 
      (BZYQD) is commonly used for treating OPF. However, the essential bioactive 
      compounds and the underlying molecular mechanisms that promote fracture repair 
      remain unclear. METHODS: We used network pharmacology and experimental animal 
      validation to address this issue. First, 147 bioactive BZYQD compounds and 32 
      target genes for treating OPF were screened and assessed. A BZYQD-bioactive 
      compound-target gene-disease network was constructed using the Cytoscape 
      software. Functional enrichment showed that the candidate target genes were 
      enriched in oxidative stress- and inflammation-related biological processes and 
      multiple pathways, including nuclear factor kappa B (NF-kappaB), and 
      mitogen-activated protein kinase (MAPK) signaling pathways. Furthermore, an OPF 
      rat model was established and treated with BZYQD. RESULTS: The results revealed 
      that BZYQD ameliorated OPF characteristics, including femoral microarchitecture, 
      biomechanical properties, and histopathological changes, in a dose-dependent 
      manner. Results of enzyme-linked immunosorbent assay showed that BZYQD reduced 
      the serum's pro-inflammatory cytokines [Tumor necrosis factor-alpha (TNF-alpha), 
      Interleukin (IL)-1beta, and IL-6] and improved oxidative stress-related factors 
      [glutathione (GSH) and superoxide dismutase (SOD)]. BZYQD significantly decreased 
      the protein expression of NF-kappaB in OPF rat femurs, suppressed NF-kappaB activation, 
      and activated the nuclear factor-erythroid factor 2-related factor (Nrf2)/heme 
      oxygenase 1 (HO-1) and p38 MAPK as well ERK pathways. CONCLUSIONS: Our results 
      suggest that BZYQD could improve inflammation and oxidative stress during 
      fracture repair by suppressing NF-kappaB and activating Nrf2/MAPK signaling pathways.
CI  - (c) 2023. The Author(s).
FAU - Hua, Zhen
AU  - Hua Z
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Dai, Shijie
AU  - Dai S
AD  - College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 
      China.
FAU - Li, Shaoshuo
AU  - Li S
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Wang, Jianwei
AU  - Wang J
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Peng, Hongcheng
AU  - Peng H
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Rong, Yi
AU  - Rong Y
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Yu, Hao
AU  - Yu H
AD  - Department of Orthopedics, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 
      China.
FAU - Liu, Mingming
AU  - Liu M
AD  - Department of Orthopedics, The Second People's Hospital of Lianyungang, 41 
      Hailian East Road, Haizhou District, Lianyungang, 222006, Jiangsu Province, 
      China. drliumingming@163.com.
LA  - eng
GR  - HB2020063/Top Talent Support Program for young and middle-aged people of Wuxi 
      Health Committee/
GR  - BE2021679/Social Development Program of Jiangsu Province/
PT  - Journal Article
DEP - 20230204
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NF-kappa B)
RN  - 0 (Nfe2l2 protein, rat)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Inflammation/pathology
MH  - Network Pharmacology
MH  - NF-E2-Related Factor 2/genetics/metabolism/therapeutic use
MH  - *NF-kappa B/metabolism
MH  - *Osteoporotic Fractures/drug therapy
PMC - PMC9898002
OTO - NOTNLM
OT  - Buzhong Yiqi Decoction
OT  - Network pharmacology
OT  - Osteoporotic fracture
COIS- The authors declare that they have no competing interests.
EDAT- 2023/02/05 06:00
MHDA- 2023/02/08 06:00
PMCR- 2023/02/04
CRDT- 2023/02/04 00:08
PHST- 2022/11/28 00:00 [received]
PHST- 2023/01/15 00:00 [accepted]
PHST- 2023/02/04 00:08 [entrez]
PHST- 2023/02/05 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2023/02/04 00:00 [pmc-release]
AID - 10.1186/s13018-023-03545-7 [pii]
AID - 3545 [pii]
AID - 10.1186/s13018-023-03545-7 [doi]
PST - epublish
SO  - J Orthop Surg Res. 2023 Feb 4;18(1):86. doi: 10.1186/s13018-023-03545-7.